Introduction
============

The hallmark of primary immune deficiencies (PID) is increased susceptibility to infection. Patients with severe antibody deficiency (defined as requiring immunoglobulin replacement), such as those with common variable immune deficiency (CVID), are known to experience recurrent infections especially of the respiratory tract and to a lesser extent the gastrointestinal (GI) tract [@b1]. Treatment with immunoglobulin replacement has been effective at reducing the frequency of serious infections [@b2],[@b3]. Adjusting the immunoglobulin dose on an individual patient basis to limit breakthrough infections \[rather than targeting a specific trough immunoglobulin IgG level\] has further improved the control of infections [@b4]. However, current practice has been unable to prevent all breakthrough infections, which can result in direct infection-related morbidity and mortality as well as complications such as bronchiectasis [@b5],[@b6]. Inflammatory complications such as autoimmunity and lymphoproliferation are known to occur in a subset of CVID patients [@b7]--[@b9]. Persistent infections result in chronic antigen stimulation which, in the context of a dysregulated immune system, could exacerbate inflammatory or lymphoproliferative disorders [@b10]. An association between cytomegalovirus (CMV) infection, an aberrant T cell compartment and inflammatory disorders in CVID patients has been hypothesized previously [@b11],[@b12].

Patients with antibody deficiency are most susceptible to infections with encapsulated bacteria (e.g. *Haemophilus influenzae*, *Streptococcus pneumoniae*) [@b13], whereas combined immune deficiency patients are also susceptible to viral infections [@b14],[@b15]. Previous studies have identified the presence of encapsulated bacteria [@b16],[@b17] and common viruses such as rhinovirus [@b18] in respiratory secretions of X-linked agammaglobulinaemia (XLA) and CVID patients. Some severe viral infections in antibody-deficient patients have also been noted, such as astrovirus encephalitis in XLA patients [@b19],[@b20] and disseminated astrovirus infection in severe combined immune deficiency (SCID) patients [@b21]. However, given the common view of antibody deficiency patients being most susceptible to bacterial infections, the importance of viral infections in these patients may be underappreciated. As well as direct virus-related pathology and increased susceptibility to secondary bacterial infections, viral infections could drive local and/or systemic inflammatory responses resulting in further pathology in a subset of antibody-deficient patients.

Here we report an audit of bacteriology and virology requests for patients attending our adult immunology clinic during a period of 2 years. This included a comparison of patients with severe immune deficiency, partial immune deficiency or no immune deficiency. The frequency and type of viral and bacterial infections are reported, as well as accompanying immunological features. Case reports of three CVID patients with persistent viral infection demonstrate potential consequences of viral infections and implications for changes to current practice are discussed.

Patients and methods
====================

A retrospective audit of all virology and bacteriology samples from patients attending the immunodeficiency clinic at Barts Health NHS Trust (London, UK) during a 2-year period (1 July 2011--30 June 2013) was carried out. A 2-year period was used to account for seasonal and annual variations. The aim of the audit was to ensure that microbiological testing conformed to international and national recommendations for infection surveillance, and where recommendations were not available that testing provided diagnostic benefit, defined as 'reasonable' likelihood of a positive finding leading to change in patient management [@b22],[@b23]. Patients were categorized as having a severe immune deficiency (patients requiring immunoglobulin replacement), a partial immune deficiency (mannan-binding ligand deficiency or specific antibody deficiency not requiring immunoglobulin replacement) or no immune deficiency (hereditary angioedema or new patients under investigation found subsequently to have no immune deficiency). The majority of patients in the severe immune deficiency group have a diagnosis of antibody deficiency (CVID, XLA or secondary hypogammaglobulinaemia), with only one patient having a combined deficiency and one with Good's syndrome.

The local policy at the time of the study was for bacteriology and virology surveillance of sputum or cough swab samples from asymptomatic known severe immunodeficiency patients at each routine visit, with additional sampling if symptomatic. Sampling from other sites (e.g. stool) was carried out only if patients were symptomatic.

Data for the clinical summaries were collected with written informed consent and in accordance with approval by the City and East London Research Ethics Committee. Ethical approval for the audit section was not required, under the guidance of the Research Ethics Committee.

Bacteriology and virology analysis
----------------------------------

Samples included in the study for microbiological analysis were respiratory (cystic sputum, cystic cough swab, bronchial washings) and stool samples. Local policy is to request extended culture ('cystic') for respiratory samples, as low pathogenicity organisms are relevant in severe immunodeficiency. For virology analysis respiratory (nose/throat swabs, throat swabs, nasopharyngeal aspirate, bronchoalveolar lavage) and stool samples were included.

A respiratory panel and a gastroenteritis panel of multiplex real-time polymerase chain reaction (PCR) were used for virological testing. The respiratory multiplex panel was modified from a previously published method [@b24], and included respiratory syncytial virus (RSV), influenza A and B viruses, parainfluenza viruses 1--3, adenoviruses, human metapneumovirus, rhinovirus and enterovirus. The gastroenteritis multiplex panel was based on the method developed by the Health Protection Agency for the 2012 Olympic preparedness [@b25], and included norovirus genotype I and II, rotavirus, adenoviruses type 40/41, astrovirus and sapovirus. For bacteriology testing, the organisms were cultured on selective media and identified by matrix assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (Bruker, Coventry, UK). Antibiotic susceptibility testing was undertaken using the British Society for Anti-microbial Chemotherapy (BSAC) method.

Statistical analysis
--------------------

Categorical data counts were analysed by the χ^2^ test and *P*-values \< 0·05 were considered significant. Data were analysed using GraphPad Prism software (La Jolla, CA, USA).

Results
=======

A 2-year retrospective audit of bacteriology and virology samples from patients with a severe immune deficiency, partial immune deficiency or no immune deficiency was carried out. The number and proportion of patients in each group with a positive result during the 2-year period was compared. The number of patients with a positive result rather than the number of positive samples was used to exclude the effect of few patients with multiple samples. There was a significant difference in the proportion of patients with a positive virology or bacteriology result between the severe, partial and no immune deficiency groups, with 39·7% (31 of 78) of the severe immune deficiency group having a positive virology result and 55·6% (89 of 160) having a positive bacteriology result ([Table 1](#tbl1){ref-type="table"}).

###### 

The number of patients with a positive virology or bacteriology result during a 2-year period

                                                                                 Virology                 Bacteriology
  ------------------------------------------------------------------------------ ------------------------ -----------------------------
  Total number of patients tested                                                153                      401
  Total number of samples (samples per patient)[](#tf1-2){ref-type="table-fn"}   1111 (7·26)              1917 (4·78)
  Number of patients with                                                                                 
  Severe antibody deficiency                                                     78                       160
  Number of patients with a positive result                                      31 (39·7%)               89 (55·6%)
  Partial immune deficiency                                                      15                       49
  Number of patients with a positive result                                      4 (26·7%)                14 (28·6%)
  No immune deficiency                                                           60                       192
  Number of patients with a positive result                                      11 (18·3%)               50 (26·0%)
  χ^2^ value, *P*-value                                                          7·485 ^\*^*P =* 0·0237   34·54 ^\*\*\*^*P* \< 0·0001

The χ^2^ test was used to compare the number of severe, partial and no deficiency patients with a positive result, for virology and bacteriology tests.

The respiratory virus screen was equivalent to nine samples and the gastrointestinal (GI) virus screen was equivalent to seven samples.

Respiratory samples were the most common type, accounting for 76% (2321 of 3037) of virology results reported and 45% (1033 of 2294) of bacteriology results, followed by stool samples accounting for 17% (520 of 3037) of virology results and 10% (234 of 2294) of bacteriology results reported. A greater proportion of the severe immune deficiency group had a positive virology or bacteriology respiratory sample compared to the partial and no immune deficiency patients ([Table 2](#tbl2){ref-type="table"}). For stool samples, the majority of patients with a positive bacteriology sample were from the severe deficiency group (four of 27), with two of 14 patients with no immune deficiency having a positive bacteriology result. Positive virology stool samples were found only in the severe antibody deficiency group.

###### 

Patients in each immune deficiency group with a positive virology or bacteriology result from respiratory or stool samples

                                        Severe       Partial      None         χ^2^ test
  ------------------------------------- ------------ ------------ ------------ ----------------------------
  Respiratory                                                                  
   Total virology patients              60           12           38           4·856 *P =* 0·0882
   Positive virology patients (%)       25 (41·7%)   3 (25·0%)    8 (21·1%)    
   Total bacteriology patients          140          34           53           16·05 *^\*\*\*^P =* 0·0003
   Positive bacteriology patients (%)   78 (55·7%)   11 (32·4%)   14 (26·4%)   
  Stool                                                                        
   Total virology patients              21           1            2            1·412 *P =* 0·4937
   Positive virology patients (%)       7 (33·3%)    0 (0·0%)     0 (0·0%)     
   Total bacteriology patients          27           6            14           1·009 *P =* 0·6038
   Positive bacteriology patients (%)   4 (14·8%)    0 (0·0%)     2 (14·3%)    

We identified the most frequently detected organisms and the sampling site for the severe immune deficiency patients. The most frequently identified viruses were rhinovirus, human metapneumovirus and parainfluenza virus 3 in respiratory samples and norovirus genotype II from stool samples ([Table 3](#tbl3){ref-type="table"}). The most frequently cultured bacteria were *H. influenzae*, *Pseudomonas* spp. and *Staphylococcus aureus*, but surprisingly only one severe immune deficiency patient had a *S. pneumoniae*-positive culture during the 2-year period ([Table 4](#tbl4){ref-type="table"}).

###### 

The number of severe immune deficiency patients with each virus and their sample site

  Virus                   Respiratory (severe deficiency)   Stool (severe deficiency)   Number of all patients
  ----------------------- --------------------------------- --------------------------- ------------------------
  Rhinovirus              12                                --                          17
  Metapneumovirus         6                                 --                          6
  Norovirus genotype II   --                                6                           6
  Parainfluenza 3         3                                 --                          5
  Adenovirus              2                                 2                           4
  Enterovirus             2                                 1                           4
  Influenza A             2                                 --                          2
  Influenza B             2                                 --                          2
  HSV1 and HSV2           1                                 --                          10
  Astrovirus              --                                2                           2
  Norovirus genotype I    --                                1                           1
  Parainfluenza 1         0                                 --                          1
  RSV                     0                                 --                          1

###### 

The number of severe immune deficiency patients with each bacterium or fungus and their sample site

  Organism                            Respiratory (severe deficiency)   Stool (severe deficiency)   Number of all patients
  ----------------------------------- --------------------------------- --------------------------- ------------------------
  *Haemophilus influenzae*            24                                0                           27
  *Pseudomonas* spp.                  22                                0                           30
  *Staphylococcus aureus*             21                                0                           46
  *Aspergillus* spp.                  10                                0                           12
  *Candida* spp.                      8                                 0                           12
  *Serratia* spp.                     7                                 0                           9
  *Stenotrophomonas maltophilia*      7                                 0                           9
  *Moraxella* spp.                    6                                 0                           6
  Methicillin-resistant *S. aureus*   5                                 0                           8
  *Enterobacter* spp.                 3                                 0                           5
  *Proteus* spp.                      2                                 0                           7
  *Streptococcus pneumoniae*          1                                 0                           4
  *Klebsiella* spp.                   1                                 0                           3
  *Citrobacter* spp.                  1                                 0                           2
  *Achromobacter xylosoxidans*        1                                 0                           1
  *Enterococcus*                      0                                 0                           4
  *Giardia lamblia*                   0                                 2                           2

Local policy has been to screen known immunodeficient patients for surveillance even if asymptomatic, as well as to sample during symptomatic episodes. However, of the positive virology isolates, 97% (98 of 101) of samples were from patients who were symptomatic at the time. There were three samples from asymptomatic patients, two of whom had no immune deficiency. Additionally, most of the positive virology samples (95 of 101; 94·1%) were from patients with a negative bacteriology result, suggesting that most positive virology episodes were not associated with secondary bacterial infections. C-reactive protein (CRP) levels were raised in 55·1% (27 out of 49 values available) of episodes associated with a positive virology result ([Fig. 1a](#fig01){ref-type="fig"}).

![C-reactive protein (CRP) and serum immunoglobulin levels at the time of positive virology result. CRP levels at the time of positive virology result are shown in (a). Serum immunoglobulin IgG, IgA and IgM (b) at the time of each positive virology result are shown. Dotted lines indicate reference ranges.](cei0181-0267-f1){#fig01}

The severe immune deficiency patients were all receiving immunoglobulin replacement at the time. During the episodes with a positive virology result, the majority of patients (96·1%) had adequate IgG replacement, with a median serum IgG level of 11·4 g/l (normal range 5·5--16·5 g/l). Immunoglobulin replacement products contain minimal amounts of other immunoglobulin isotypes, and as such 88·2% of patients had low serum IgA levels (median 0·11 g/l, normal range 0·8--4·0 g/l) and 62·7% had low serum IgM levels (median 0·11g/l, normal range 0·4---2·0 g/l) ([Fig. 1b](#fig01){ref-type="fig"}). Immunoglobulin levels from severe immune deficiency patients with a positive virology result were compared to the total cohort of severe immune deficiency patients described previously [@b26]. Low levels of IgA, but not IgG or IgM, were significantly more prevalent in the patients with a positive virology result (Supporting information, [Fig. S1](#sd1){ref-type="supplementary-material"}), suggesting a role for IgA in protection from viral infection. Moreover, positive virology results were more frequent in the severe immune deficiency patients with low IgA (Supporting information, [Table S1](#sd1){ref-type="supplementary-material"}).

We identified severe immune deficiency patients with 'persistent' viral detection, defined as two or more positive detections of the same virus \>8 weeks apart. Three CVID patients during the 2-year period were found to have a persistent norovirus infection, with one of these patients additionally having a persistent rhinovirus infection ([Table 5](#tbl5){ref-type="table"}). All patients were symptomatic. Patients 1 and 3 experienced severe weight loss and both required large increases in immunoglobulin dose to maintain trough IgG levels. Patient 1 cleared norovirus after 9 months, regaining weight, and has reduced immunoglobulin requirement ([Fig. 2a](#fig02){ref-type="fig"}). The other two patients continue to excrete norovirus after 30 and 16 months, respectively; both remain intermittently symptomatic and one has required long-term parenteral nutrition ([Fig. 2b](#fig02){ref-type="fig"},[c](#fig02){ref-type="fig"}). Further details of these three cases can be found in the Supporting information.

![Three common variable immune deficiency (CVID) patients with persistent viral infections. Serum immunoglobulin IgG, IgA, IgM and the time--course of diarrhoeal symptoms and treatments are shown for patient 1 (a), patient 2 (b) and patient 3 (c). Positive norovirus samples (filled diamonds), negative norovirus samples (open diamonds), positive rhinovirus samples (filled circles), negative rhinovirus samples (open circles), positive rotavirus antigen (plus signs), positive respiratory syncytial virus (RSV) samples (crosses) and negative RSV samples (dots) are shown. Light grey bars indicate intermittent symptoms.](cei0181-0267-f2){#fig02}

###### 

Characteristics of three severe antibody deficiency patients with a persistent viral infection

  Antibody deficiency                          Patient 1^‡^CVID   Patient 2^†^CVID   Patient 3^†^CVID   
  -------------------------------------------- ------------------ ------------------ ------------------ --------
  Months of infection                          9                  30                 16                 11
  Virus clearance                              Yes                No                 No                 Yes
  Number of positive results                   13                 12                 29                 10
  Number of negative results since clearance   1                  --                 --                 13
  At the time of first positive result                                                                  
   IgG (5·5--16·5)                             10.0               13·9               8·7                9·1
   IgA (0·8--4·0)                              0·06               0·14               \<0·04             \<0·04
   IgM (0·4--2·0)                              \<0·06             1·36               0·45               0·45
   Lymphocyte count × 10^9^/l                  1·2                1·4                8·1                9·5
   CD3^+^ count × 10^6^/l (918--2023)          971                720                9974               8927
   CD4^+^ count × 10^6^/l (455--1820)          402                466                2668               2750
   CD8^+^ count × 10^6^/l (140--906)           577                261                7109               5892
   CD56^+^ count × 10^6^/l (90--600)           94                 122                345                278

Reference ranges are shown in parentheses. CVID = common variable immune deficiency; Ig = immunoglobulin.

Lymphocyte count reference ranges: ^†^(1·2--3·5) × 10^9^/l ^‡^(1·5--4·0) × 10^9^/l.

Discussion
==========

Current national standards recommend routine bacteriology screening of CVID patients, but recommend virology screening only for SCID patients [@b22],[@b23]. We observed a greater prevalence of both bacterial and viral infections in severe immune deficient patients. A high prevalence of viral infections in antibody deficiency patients has been identified previously [@b27],[@b28], and our audit suggests that screening for viruses in symptomatic patients and for infection control purposes is useful.

In agreement with several other studies, the most frequently cultured bacteria in severe immunodeficient patients was *H. influenzae* [@b16],[@b18],[@b29]. However, we observed a lower frequency of other common upper respiratory tract pathogens such as *S. pneumoniae* than previous studies [@b17],[@b30], which may reflect our policy of increasing immunoglobulin dose to prevent breakthrough infection [@b2],[@b4]. Opportunistic infections such as *Pseudomonas* spp. and *S. aureus* were relatively more common. A relatively high proportion of our cohort has bronchiectasis [@b26], which may partially explain the more common occurrence of these pathogens. Although some isolates may have represented upper airway sample contamination, the majority occurred in symptomatic patients and may require more aggressive management. For those with viral infection, there was only a low prevalence of co-existing or secondary bacterial infections in this study compared to others [@b27], which could reflect our practice of prescribing patient-held antibiotics to be used as soon as patients are symptomatic, in accordance with national and international consensus [@b23],[@b31].

The most common detected viruses, rhinovirus and norovirus, probably reflect the high prevalence of these viruses in the general population, as infections were community-acquired. Rhinovirus was identified as the most common viral pathogen in sinus lavage samples from asymptomatic antibody-deficient patients [@b18] and in sputum samples from symptomatic antibody-deficient patients [@b27]. Norovirus was also the most common faecal pathogen identified in antibody-deficient children, although almost half were asymptomatic [@b28], which is in contrast to our study where all positive patients were symptomatic, as stool sampling was carried out only on symptomatic patients. There was a surprisingly low occurrence of respiratory syncytial virus (RSV) in the patients with severe antibody deficiency. Palivizumab is a monoclonal antibody administered intramuscularly to prevent RSV infection in high-risk children, suggesting that systemic immunoglobulins can protect against RSV. The high level of replacement immunoglobulin treatment used in our patients should contain some level of anti-RSV antibodies, as the majority of the adult population are seropositive [@b32], which may similarly offer protection against certain pathogens such as RSV. However, for other pathogens, serum IgG replacement may not offer protection at the mucosal surface and mucosal IgA, which is not replaced with treatment, may be more important. Although antibody deficiency is not usually thought to result in an increased risk of common viral infections, CVID is a heterogeneous group of diseases with varying molecular mechanisms. Several studies have noted defects in T cell number and function in some CVID patients [@b8],[@b33]. Additionally, patients with an inflammatory/lymphoproliferative CVID phenotype may be on immunosuppressive medication that could further suppress cell-mediated immunity. As such, a subset of CVID patients may be more susceptible to viral infections than considered previously.

The three case reports demonstrate that in a small proportion of antibody-deficient patients viral infections may become persistent. Persistent norovirus infection has been described in hypogammaglobulinaemic patients with chronic lymphocytic leukaemia [@b34] and following allogeneic haematopoetic stem cell transplantation, and has been associated with significant morbidity and mortality [@b35]. A study of paediatric PID patients also noted that norovirus shedding persisted for a median of 9·5 months, additionally posing an infection control risk [@b28]. Similarly, rhinovirus was also persistently isolated for \>2 months from half of symptomatic antibody-deficient patients [@b27]. In hypogammaglobulinaemic patients rhinovirus shedding was found to last for a mean of 40 days, compared to 10 days in healthy controls [@b36]. In the absence of molecular typing it is difficult to conclude whether the sequential positive viral isolates reflect genuine persistence of a single strain or reinfection with multiple strains, as shown for rhinovirus [@b36].

A limitation of this study is that it was retrospective, and so may be open to sampling bias. Additionally, the virology-positive results rely on detection of viral RNA by PCR, whereas bacteriology-positive results are from cultured growth, which may overestimate the prevalence of viral infection caused by the pathogens tested, while failing to detect other viruses not specifically screened for. However, the majority of virology positive results in this study were from symptomatic episodes in the absence of positive bacteriology culture. A further limitation of this study is that the sensitivity of multiplex detection assays may be lower than that of monoplex assays, as has been shown for a rhinovirus assay [@b37], leading to an underestimation of positive viral detections.

Treatment of norovirus with oral immunoglobulin has been shown to lead to a faster resolution of symptoms after 7 days of treatment, probably through local mucosal blocking of virus [@b38]. The three case reports here suggest that intravenous replacement with immunoglobulin products with a higher IgA content may also be helpful, although it was not effective in all patients, so further study is needed. Treatment of persistent rhinovirus in antibody-deficient patients with IFN-α2a and ribavirin has also been shown to clear rhinovirus rapidly from sputum samples [@b39].

As a result of this audit, we have made changes to our practice. Bacteriology and virology sampling of symptomatic immunodeficient patients has proved useful, but asymptomatic patients will not be sampled routinely for virology, except for follow-up of previously detected virus. Active treatment of viral infection with appropriate anti-virals for high-risk patients, or where virus is persistent, would be considered. For patients with persistent infection we consider the options of oral immunoglobulin or IgA-containing immunoglobulin replacement on a case-by-case basis. For infection control measures during clinic visits, patients known to be infected with, e.g. norovirus, are isolated and there is continued emphasis on hand-washing and surface decontamination for all patients. There is continued recommendation for influenza vaccine for at-risk patients and household contacts. Our audit suggests that viral infection may be important for patients with severe antibody deficiency. Further work is required to assess the benefit of a more proactive approach to diagnosis and treatment of viral infection in this patient group.
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**Fig. S1.** The number of patients with low immunoglobulin (Ig)G, IgA or IgM from the total severe immune deficiency Barts cohort is compared to the severe immune deficiency patients with a positive virology result. For the total Barts cohort, IgG values are the average during the year up to June 2013; for the IgA and IgM levels values, where available, were prior to treatment.

**Table S1.** Number of virus detections in severe immune deficiency patients with different serum IgA levels.
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